Observational studyJournal of the ASEAN Federation of Endocrine Societies2025
Prevalence of Hepatic Fibrosis and Performance of Non-invasive Liver Fibrosis Scores in an Eastern Indian Diabetic Population with NAFLD.
Observational study in Journal of the ASEAN Federation of Endocrine Societies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Noninvasive Detection of Clinically Significant Fibrosis in Biopsy-Proven MASLD: A Retrospective Cross-Sectional Diagnostic Accuracy Study.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease, especially in patients with type 2 diabetes mellitus (T2DM). Significant prevalence of liver fibrosis has been observed in Indian diabetic patients with fatty liver. Early detection of liver fibrosis in persons with diabetes prevents serious problems. This study compares non-invasive liver fibrosis scores and vibration-controlled transient elastography (VCTE) utilising FIBROSCAN™ to assess fibrosis prevalence in patients with T2DM and NAFLD. Methodology: This cross-sectional, observational study enrolled 351 patients with T2DM and NAFLD from September to October 2023 from eight West Bengal diabetes facilities. Liver stiffness measurement (LSM) via VCTE was used to detect fibrosis. Non-invasive tests (NITs), including fibrosis-4 index (FIB-4), NAFLD fibrosis score (NFS), fibrotic NASH-index (FNI), and AST to platelet ratio index (APRI) were also calculated. To evaluate NIT diagnostic performance, AUROC curve calculations were used. Results: Among patients with T2DM, 26.5% had fibrosis and 3.13% of individuals had advanced fibrosis (≥F3), whereas 11.97% had substantial fibrosis (≥F2). Fibrotic NASH-index could detect fibrosis best with area under the curve (AUROC) >0.70, whereas FIB-4 and NFS were better (AUROC >0.8) to identify advanced fibrosis, and APRI struggle to diagnose severe fibrosis. Conclusion: In patients with T2DM with NAFLD, VCTE detects fibrosis. FNI is best tool for detection of fibrosis, whereas FNI and NFS are better for distinguishing advanced fibrosis in such patients. To increase fibrosis identification in this population, multiple diagnostic approaches are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.